When Renerve makes its IPO on the ASX today, it will join Orthocell as one of only two nerve-repair companies to be listed on ...

The following is a summary of “Local molecular signature of human peripheral neuropathic pain,” published in the November ...

A new study from Michigan Medicine suggests that following a low-calorie diet and doing high-intensity exercise could reduce ...

Leerink Partners analyst Mike Kratky maintained a Buy rating on AxoGen (AXGN – Research Report) on November 25 and set a price target of $0.00.

An international team of researchers has discovered a new component of the peripheral nervous system that acts by increasing ...

A low calorie diet and high intensity exercise can reduce nerve damage in prediabetic mice, according to a Michigan Medicine ...

Scientists examine the effectiveness of an antibody targeting cell adhesion molecule 1 in alleviating pain-induced neuronal activation. Cell surface proteins are essential for facilitating cell ...

Discover various promising treatments in development to address the unmet needs of people with Charcot–Marie–Tooth disease.

Eagle Asset Management Inc. bought a new stake in AxoGen, Inc. (NASDAQ:AXGN – Free Report) in the third quarter, according to ...

In this study, 33 patients with liver cirrhosis were evaluated clinically and electrophysiologically to detect any evidence of peripheral neuropathy. Nerve conduction studies were performed in the ...